- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02569957
Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Evaluation of the Addition of N-Acetylcysteine to Topotecan in the Tumor Microenvironment of Persistent or Recurrent High Grade Endometrioid or Serous Ovarian Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To estimate the proportion of subjects with persistent or recurrent high grade endometrioid or serous ovarian carcinoma who demonstrate a downregulation of monocarboxylate transporter 4 (MCT4) in the ovarian stroma in response to exposure to topotecan (topotecan hydrochloride) and N-acetylcysteine (NAC) (acetylcysteine) as compared to topotecan alone.
SECONDARY OBJECTIVES:
I. To determine the expression levels of caveolin 1 (Cav-1), solute carrier family 16 (monocarboxylate transporter), member 1 (MCT1), translocase of outer mitochondrial membrane 20 homolog (yeast) (TOMM20), fatty acid binding protein 4, adipocyte (FABP4), hypoxia inducible factor 1, alpha subunit (HIF-1 alpha) and NF kappaB activating protein (NFκB) in pathological samples of tumors after therapy with NAC relative to samples taken at time of initial diagnosis.
II. To assess the potential impact of NAC on progression free survival, overall survival, objective tumor response- complete or partial, and duration of response.
III. To estimate the proportion of subjects who survive progression free for at least 6 months and the proportion of patients who have objective tumor response, complete or partial in response to therapy IV. To assess safety and tolerability of NAC plus topotecan treatment in subjects with endometrioid or serous ovarian carcinoma by Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0 criteria.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive topotecan hydrochloride intravenously (IV) over 30 minutes on days 1, 8, and 15 (+/- 1 day window for each treatment day). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive topotecan hydrochloride as in Arm I. Patients also receive acetylcysteine IV over 60 minutes on days 1, 8, 15, and 22 (+/- 1 day window for each treatment day) and acetylcysteine orally (PO) twice daily (BID) on days 2-7, 9-14, 16-21, and 23-28, unless administration window was utilized. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 24 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient must have persistent or recurrent high grade endometrioid or serous ovarian, primary peritoneal or fallopian tube carcinoma. Histologic documentation of the original primary tumor is required via the pathology report.
- All patients must have measurable disease that is amenable to biopsy. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded). Each lesion must be ≥20 mm when measured by conventional techniques including palpation, plain film x-ray, CT, and MRI, or ≥ 10 mm when measured by high resolution CT.
- Patient must have at least one target lesion to be used to assess response on this protocol as defined by RECIST 1.1. Tumors within a previously irradiated field will be designated as non-target lesions unless progression is documented or a biopsy is obtained to confirm persistent disease at least 90 days following completion of radiation therapy.
- Patients must have a GOG performance status of 0, 1, or 2.
- Patients must be free of active infections requiring antibiotics, with the exception of uncomplicated urinary tract infections (UTIs).
- Any hormonal therapy directed at the tumor must be discontinued at least one week prior to initiation of therapy. Continuation of hormone replacement therapies is permitted.
- Any other prior therapy directed at the tumor, including immunologic agents, must be discontinued at least 3 weeks prior to initiation of therapy.
- Patients must have had at least one prior platinum/taxane combination chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatin compound. This initial treatment may include intraperitoneal therapy, high dose therapy, consolidation, noncytotoxic agents, or extended therapy.
Patients must be platinum resistant- defined as progressive disease while receiving platinum therapy or within 6 months of completing first line platinum therapy or patients who have progressive disease after two lines of platinum based treatment.
- Cytotoxic regimens are any that include agents that target the genetic and/or mitotic apparatus of the dividing cells, resulting in dose limiting toxicity to the bone marrow or gastrointestinal mucosa
- Patients are allowed to receive, but not required to receive biologic (noncytotoxic) therapy as part of their treatment regimen, e.g. bevacizumab.
Patients Must Have Adequate:
- Bone Marrow Function: Absolute Neutrophil Count greater than or equal to 1000/mcl. Platelets greater than or equal to 100,000/mcl. Hemoglobin greater than 10 g/dl. (Patients may be transfused to achieve this hemoglobin.)
- Renal Function: creatinine less than or equal to 1.5 x upper limit of normal, CTCAE v 4.0 grade 1.
- Hepatic Function: bilirubin less than or equal to 1.5 x upper limit of normal, CTCAE v 4.0 grade 1. Asparate transaminase (AST) and alkaline phosphatase less than or equal to 2.5 x upper limit of normal, CTCAE v 4.0 grade 1.
- Coagulation: PT, PTT less than or equal to 1 to 1.5 x upper limit of normal CTCAE v 4.0 grade 1 except for patients on therapeutic anticoagulation.
- Neurologic Function: neuropathy (sensory and motor) less than or equal to CTCAE v 4.0 grade 1.
- Patients must have signed an approved informed consent and authorization permitting release of personal health information.
- Patients must meet pre-entry requirements as specified.
- In the unlikely event that patients are still of childbearing potential, these patients must have a negative serum pregnancy test within 72 hours prior to initiating protocol therapy and be practicing an effective form of contraception during protocol therapy and for at least 4 weeks following completion of protocol therapy.
- Patients must be 18 years of age or older.
- Patients must not be receiving any other investigational agent.
- Patients must be able to swallow whole pills. -
Exclusion Criteria:
- Patients who have had previous treatment with topotecan.
- Patients who have had more than 4 prior chemotherapy regimens.
- Patients who have received radiation to more than 25% of marrow-bearing areas.
- Patients with a history of other invasive malignancies are excluded if there is any evidence of other malignancy being present within the last 3 years.
- Patients who have received prior chemotherapy for any abdominal or pelvic tumor other than for treatment of ovarian carcinoma within the last 3 years are excluded. Patients may have received prior chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration and the patient remains free of recurrent of metastatic disease.
- Pregnant or nursing women or women of childbearing potential unless using effective contraception as determined by the investigator. -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm I (topotecan hydrochloride)
Patients receive topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15 (+/- 1 day window for each treatment day).
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
|
Experimental: Arm II (topotecan hydrochloride, acetylcysteine)
Patients receive topotecan hydrochloride as in Arm I. Patients also receive acetylcysteine IV over 60 minutes on days 1, 8, 15, and 22 (+/- 1 day window for each treatment day) and acetylcysteine PO BID on days 2-7, 9-14, 16-21, and 23-28, unless administration window was utilized.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
Given IV and PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Patients Who Demonstrate a Downregulation of MCT4
Time Frame: Baseline to up to day 20 after first course of topotecan hydrochloride
|
The two-sided Fisher's exact test with alpha 0.05 will be used to compare the proportions of subjects who demonstrate a downregulation of MCT4 between subjects treated with topotecan hydrochloride and NAC and topotecan hydrochloride alone.
|
Baseline to up to day 20 after first course of topotecan hydrochloride
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Expression Levels of Cav-1 in Tissue Samples
Time Frame: Baseline to up to day 20 after first course of topotecan hydrochloride
|
Evaluated in a generalized linear mixed effects model adjusting for the random subject effects.
The expression levels will be log or otherwise transformed, if necessary, to satisfy the normal distribution assumption of the model.
The fitted model will be used to evaluate the post-treatment change in the expression levels.
|
Baseline to up to day 20 after first course of topotecan hydrochloride
|
Change in Expression Levels of MCT1 in Tissue Samples
Time Frame: Baseline to up to day 20 after first course of topotecan hydrochloride
|
Evaluated in a generalized linear mixed effects model adjusting for the random subject effects.
The expression levels will be log or otherwise transformed, if necessary, to satisfy the normal distribution assumption of the model.
The fitted model will be used to evaluate the post-treatment change in the expression levels.
|
Baseline to up to day 20 after first course of topotecan hydrochloride
|
Change in Expression Levels of TOMM20 in Tissue Samples
Time Frame: Baseline to up to day 20 after first course of topotecan hydrochloride
|
Evaluated in a generalized linear mixed effects model adjusting for the random subject effects.
The expression levels will be log or otherwise transformed, if necessary, to satisfy the normal distribution assumption of the model.
The fitted model will be used to evaluate the post-treatment change in the expression levels.
|
Baseline to up to day 20 after first course of topotecan hydrochloride
|
Change in Expression Levels of FABP4 in Tissue Samples
Time Frame: Baseline to up to day 20 after first course of topotecan hydrochloride
|
Evaluated in a generalized linear mixed effects model adjusting for the random subject effects.
The expression levels will be log or otherwise transformed, if necessary, to satisfy the normal distribution assumption of the model.
The fitted model will be used to evaluate the post-treatment change in the expression levels.
|
Baseline to up to day 20 after first course of topotecan hydrochloride
|
Change in Expression Levels of HIF-1 Alpha in Tissue Samples
Time Frame: Baseline to up to day 20 after first course of topotecan hydrochloride
|
Evaluated in a generalized linear mixed effects model adjusting for the random subject effects.
The expression levels will be log or otherwise transformed, if necessary, to satisfy the normal distribution assumption of the model.
The fitted model will be used to evaluate the post-treatment change in the expression levels.
|
Baseline to up to day 20 after first course of topotecan hydrochloride
|
Change in Expression Levels of NFκB in Tissue Samples
Time Frame: Baseline to up to day 20 after first course of topotecan hydrochloride
|
Evaluated in a generalized linear mixed effects model adjusting for the random subject effects.
The expression levels will be log or otherwise transformed, if necessary, to satisfy the normal distribution assumption of the model.
The fitted model will be used to evaluate the post-treatment change in the expression levels.
|
Baseline to up to day 20 after first course of topotecan hydrochloride
|
Change in Number of Circulating Tumor Cells
Time Frame: Baseline to day 29
|
Compared pre-therapy and post- 1 cycle of therapy with a Fisher's exact test.
|
Baseline to day 29
|
Progression-free Survival
Time Frame: Up to 24 months
|
Compared between the two arms using the log-rank test.
|
Up to 24 months
|
Overall Survival
Time Frame: Up to 24 months
|
Compared between the two arms using the log-rank test.
|
Up to 24 months
|
Objective Tumor Response Rates
Time Frame: Up to 24 months
|
Evaluated using the exact binomial confidence intervals and compared between the two arms using the Fisher's exact test.
|
Up to 24 months
|
Duration of Response
Time Frame: Up to 24 months
|
Compared between the two arms using the two-sample Wilcoxon test.
|
Up to 24 months
|
Proportion of Patients Experiencing Adverse Events, Evaluated Using the National Cancer Institute CTCAE Version 4.0
Time Frame: Up to 24 months
|
Tabulated and reported with the corresponding exact binomial confidence intervals.
|
Up to 24 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Russell Schilder, MD, Thomas Jefferson University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Disease Attributes
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Neoplasms
- Carcinoma
- Recurrence
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Protective Agents
- Topoisomerase Inhibitors
- Respiratory System Agents
- Antioxidants
- Topoisomerase I Inhibitors
- Antidotes
- Free Radical Scavengers
- Expectorants
- Topotecan
- Acetylcysteine
- N-monoacetylcystine
Other Study ID Numbers
- 15P.404
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Fallopian Tube Carcinoma
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingOvarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditionsUnited States, Puerto Rico
-
National Cancer Institute (NCI)CompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal CarcinomaUnited States
-
Roswell Park Cancer InstituteCompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Tumor | Fallopian Tube Endometrioid Tumor | Ovarian Endometrioid Tumor | Fallopian Tube Mucinous Neoplasm | Fallopian Tube Serous Neoplasm | Ovarian Serous Tumor | Ovarian Mucinous...United States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal CarcinomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsCompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian... and other conditionsUnited States, Puerto Rico
-
National Cancer Institute (NCI)CompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal CarcinomaUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell AdenocarcinomaUnited States
-
M.D. Anderson Cancer CenterAstraZeneca; Aravive Biologics IncActive, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditionsUnited States
-
Roswell Park Cancer InstituteActive, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Refractory Ovarian... and other conditionsUnited States
Clinical Trials on Topotecan Hydrochloride
-
CelgeneCompletedSmall Cell Lung CancerUnited States, United Kingdom, Australia, France, Canada, Netherlands, Poland, Spain, Switzerland, Italy, Denmark, Hungary, Germany, Bulgaria, Czechia, Austria, Belgium
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedMyelodysplastic Syndromes | LeukemiaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedLung CancerUnited States
-
National Cancer Institute (NCI)CompletedSarcomaUnited States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
-
NYU Langone HealthOSI PharmaceuticalsTerminated
-
National Cancer Institute (NCI)CompletedRecurrent Small Cell Lung CarcinomaUnited States, Singapore
-
NCIC Clinical Trials GroupCompletedBrain and Central Nervous System TumorsCanada
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)TerminatedOvarian Cancer | Primary Peritoneal Cavity CancerUnited States, Canada